Abstract: The present invention relates to new nucleic acid sequences derived from the ITS (Internal Transcribed Spacer) region, between the 16S and 23S rRNA genes, to be used for the specific detection and/or identification of Serratia species, in particular of Serratia marcescens, Serratia ficaria and/or Serratia fonticola, in a biological sample. The present invention relates also to a method for the specific detection and/or identification of Serratia species, in particular Serratia marcescens, Serratia ficaria and/or Serratia fonticola, using said new nucleic acid sequences derived from the ITS region. It relates also to nucleic acid primers to be used for the amplification of said spacer region of Serratia species in a sample.
Abstract: The present invention is directed to peptides, and nucleic acids encoding them, derived from the Hepatitis C Virus (HCV). The peptides are those which elicit a CTL and/or HTL response in a host. The invention is also directed to compositions and vaccines for prevention and treatment of HCV infection and diagnostic methods for detection of HCV exposure in patients.
Type:
Application
Filed:
May 31, 2005
Publication date:
May 4, 2006
Applicants:
Innogenetics, N.V., EPIMMUNE INC.
Inventors:
Marie-Ange Buyse, Geert Maertens, Erik Depla, Ignace Lasters, Johan Desmet, Denise Baker, Robert Chesnut, Mark Newman, Alessandro Sette, John Sidney, Scott Southwood
Abstract: Multimer peptides (e.g. 30- to 45-mer peptides) derived from hepatitis C virus envelope proteins reacting with the majority of anti-HCV antibodies present in patient sera are described. The usage of the latter peptides to diagnose, and to vaccinate against, an infection with hepatitis C virus is also disclosed.
Abstract: The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E1/E2 characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disulphide bond cleavage agent. The present invention also relates to a composition isolated by such a method. The present invention also relates to the diagnostic and therapeutic application of these compositions. Furthermore, the invention relates to the use of HCV E1 protein and peptides for prognosing and monitoring the clinical effectiveness and/or clinical outcome of HCV treatment.
Type:
Grant
Filed:
October 10, 2001
Date of Patent:
April 11, 2006
Assignee:
Innogenetics N.V.
Inventors:
Geert Maertens, Fons Bosman, Guy De Martynoff, Marie Ange Buyse
Abstract: The present invention relates to a pharmaceutical composition comprising a non-viable cell lysate and at least one antiflocculant and/or antisedimentation agent(s). The pharmaceutical composition of the present invention comprising the cell lysate is in the form of a solution or a suspension or a lyophilisate, in particular, the homogenized cell lysate compositions are in the form of solutions or suspensions or lyophilisates. The present invention further discloses processes for the production and the use of the pharmaceutical composition.
Type:
Application
Filed:
November 25, 2003
Publication date:
February 23, 2006
Applicant:
Innogenetics N.V.
Inventors:
Chris Vervaet, Jean-Paul Remon, Bernard Delaey, Peter De Waele
Abstract: The invention relates to recombinantly or synthetically produced HCV E1 envelope proteins or parts thereof comprising disulfides between specific cysteine residues. The invention further relates to viral-like particles and compositions comprising said HCV E1 envelope proteins or parts thereof as well as to methods using said HCV E1 envelope proteins or parts thereof, and to kits comprising said HCV E1 envelope proteins or parts thereof.
Type:
Application
Filed:
March 8, 2005
Publication date:
February 16, 2006
Applicant:
INNOGENETICS N.V
Inventors:
Stany Depraetere, Erik Depla, Gert Verheyden, Alfons Bosman
Abstract: A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein. The tau protein can be obtained from a brain homogenate, itslf isolated from the cerebral cortex of a patient having Alzheimer's disease. Further, a method of detecting the tau protein is claimed.
Type:
Application
Filed:
August 20, 2004
Publication date:
January 12, 2006
Applicant:
N.V. Innogenetics S.A.
Inventors:
Marc Mercken, Eva-Maria Mandelkow, Marc Vandermeeren, Eugeen Vanmechelen, Andre Van De Voorde
Abstract: The present invention relates to new genomic nucleotide sequences and amino acid sequences corresponding to the coding region of these genomes. The invention relates to new HCV types and subtypes sequences which are different from the known HCV types and subtypes. More particularly, the present invention relates to new HCV type 7 sequences, new HCV type 9 sequences, new HCV type 10 and new HCV type 11 sequences. Also, the present invention relates to new HCV type 1 sequences of subtypes 1d, 1e, 1f and 1g; new HCV type 2 sequences of subtypes 2e, 2f, 2g, 2h, 2I, 2k and 2l; new HCV type 3 sequences of subtype 3g, new HCV type 4 sequences of subtypes 4k, 4l and 4m; a process for preparing them, and their use for diagnosis, prophylaxis and therapy. More particularly, the present invention provides new type-specific sequences of the Core, the E1 and the NS5 regions of new HCV types 7, 9, 10 and 11, as well as of new variants (subtypes) of HCV types 1, 2, 3 and 4.
Abstract: The present invention relates to 16S-23S rRNA spacer sequences from Staphylococcus aureus and their use in a method for detection and/or identification of Staphylococcus aureus. The invention further relates to a method for detection and identification of Staphylococcus aureus in a sample, involving the steps of: (i) optionally releasing, isolating and/or concentrating the polynucleic acids present in the sample; (ii) optionally amplifying the 16S-23S rRNA spacer region, or a part thereof, with at least one primer pair; (iii) detecting the presence of a 16S-23S rRNA spacer sequence; and (iv) identifying the Staphylococcus aureus present in the sample from the nucleic acid(s) detected in the sample.
Type:
Application
Filed:
July 21, 2004
Publication date:
June 30, 2005
Applicant:
INNOGENETICS N.V.
Inventors:
Geert Jannes, Rudi Rossau, Hugo Van Heuverswyn
Abstract: A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein. The tau protein ca be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.
Abstract: The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E1/E2, characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disulphide bond cleavage agent. The present invention also relates to a composition isolated by such a method. The present invention also relates to the diagnostic and therapeutic application of these compositions. Furthermore, the invention relates to the use of HCV E1 protein and peptides for prognosing and monitoring the clinical effectiveness and/or clinical outcome of HCV treatment.
Type:
Grant
Filed:
September 12, 1997
Date of Patent:
May 10, 2005
Assignee:
Innogenetics N.V.
Inventors:
Geert Maertens, Fons Bosman, Guy De Martynoff, Marie-Ange Buyse
Abstract: The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of: contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe from about 10 to about 40 nucleotides, with said probe being liable to hybridize to a region being in the domain extending from nucleotide at position ?291 to nucleotide at position ?66 of the 5? untranslated region of one of the HCV isolates represented by their cDNA sequences, with said numbering of position beginning with the first ATG codon of the open reading frame encoding the HCV polyprotein, or with said probe being complementary to the above-defined probes, detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV isolate to be iden
Type:
Grant
Filed:
July 6, 2001
Date of Patent:
May 10, 2005
Assignee:
Innogenetics N.V.
Inventors:
Geert Maertens, Lieven Stuyver, Rudi Rossau, Hugo Van Heuverswyn
Abstract: The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of: contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe from about 10 to about 40 nucleotides, with said probe being liable to hybridize to a region being in the domain extending from nucleotide at position ?291 to nucleotide at position ?66 of the 5? untranslated region of one of the HCV isolates represented by their cDNA sequences, with said numbering of position beginning with the first ATG codon of the open reading frame encoding the HCV polyprotein, or with said probe being complementary to the above-defined probes, detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV isolate to be iden
Type:
Grant
Filed:
July 6, 2001
Date of Patent:
May 3, 2005
Assignee:
Innogenetics N.V.
Inventors:
Geert Maertens, Lieven Stuyver, Rudi Rossau, Hugo Van Heuverswyn
Abstract: The current invention relates to a previously unrecognized clade of HCV genotypes as well as to diagnostic, prophylactic and therapeutic applications of nucleic acids, proteins, and antibodies to said protein, derived of or based on the newly characterized hepatitis C viruses.
Type:
Application
Filed:
August 27, 2004
Publication date:
March 31, 2005
Applicant:
INNOGENETICS
Inventors:
Erwin Sablon, Wim Quint, Leen-Jan Van Doorn
Abstract: Peptide sequences are provided which are capable of mimicking proteins encoded by HCV for use as reagents for screening of blood and blood products for prior exposure to HCV. The peptides are at least 5 amino acids long and can be used in various specific assays for the detection of antibodies to HCV, for the detection of HCV antigens, or as immunogens.
Type:
Grant
Filed:
January 15, 2002
Date of Patent:
March 29, 2005
Assignee:
Innogenetics N.V.
Inventors:
Robert J. DeLeys, Dirk Pollet, Geert Maertens, Hugo Van Heuverswijn
Abstract: The current invention relates to the field of detection and identification of clinically important fungi. More particularely, the present invention relates to species specific probes originating from the Internal Transcribed Spacer (ITS) region of rDNA for the detection of fungal species such as Candida albicans, Candida parapsilosis, Candida tropicalis, Candida kefyr, Candida krusei, Candida glabrata, Candida dubliniensis, Aspergillus flavus, Aspergillus versicolor, Aspergillus nidulans, Aspergillus fumigatus, Cyptococcus neoformans and Pneumocystis carinii in clinical samples, and methods using said probes.
Type:
Grant
Filed:
September 15, 2000
Date of Patent:
February 22, 2005
Assignees:
Innogenetics, N.V., Enterprise Ireland
Inventors:
Terry Smith, Majella Maher, Cara Martin, Geert Jannes, Rudi Rossau, Marjo Van Der Weide
Abstract: Multimer peptides (e.g. 30- to 45-mer peptides) derived from hepatitis C virus envelope proteins reacting with the majority of anti-HCV antibodies present in patient sera are described. The usage of the latter peptides to diagnose, and to vaccinate against, an infection with hepatitis C virus is also disclosed.
Abstract: The present invention relates to peptides or polypeptides comprising an HCV NS5 protein or a part thereof or a derivative of said peptide or polypeptide, HCV NS5 protein or part thereof wherein at least one cysteine is reversibly or irreversibly modified. These modified HCV NS5 proteins have advantageous properties both for diagnostic and therapeutic/prophylactic applications.
Type:
Application
Filed:
May 28, 2004
Publication date:
January 20, 2005
Applicant:
INNOGENETICS N.V.
Inventors:
Erik Depla, Geert Maertens, Fons Bosman
Abstract: Antibodies to two new epitopes on the HCV envelope proteins were identified which allow routine detection of native HCV envelope antigens, in tissue or cells derived from the host. The new epitopes are: the E1 region aa 307-326 and the N-terminal hyper variable region of E2 aa 395-415. Surprisingly, we characterised an antibody that reacts with various sequences of the hypervariable domain of E2. Specific monoclonal antibodies directed against these epitopes and allowing routine detection of viral antigen are described.
Type:
Grant
Filed:
December 13, 2002
Date of Patent:
January 11, 2005
Assignee:
Innogenetics N.V.
Inventors:
Geert Maertens, Erik Depla, Marie-Ange Buyse
Abstract: Peptide sequences are provided which are capable of mimicking proteins encoded by HCV for use as reagents for screening of blood and blood products for prior exposure to HCV. The peptides are at least 5 amino acids long and can be used in various specific assays for the detection of antibodies to HCV, for the detection of HCV antigens, or as immunogens.
Type:
Application
Filed:
April 13, 2004
Publication date:
January 6, 2005
Applicant:
INNOGENETICS, S.A.
Inventors:
Robert Deleys, Dirk Pollet, Geert Maertens, Hugo Van Heuverswijn